Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.